Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Kura Oncology. The associated price target remains the same with $24.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Charles Zhu has given his Buy rating due to a combination of factors including Kura Oncology’s strategic advancements and financial stability. The company is progressing well towards the PDUFA date for ziftomenib, expected on November 30, 2025, which is a crucial milestone for their treatment of relapsed/refractory NPM1-mutated AML. Kura’s management has demonstrated commercial readiness by planning to engage with a significant number of healthcare professionals, focusing on both academic and community centers.
Additionally, Kura Oncology’s financial position is strong, with approximately $610 million in pro forma cash, providing a runway into 2027. This financial stability supports their ongoing and future clinical trials, including the anticipated KOMET-017 readouts. The company’s strategic interactions with the FDA and their preparations for a commercial launch further bolster confidence in their ability to achieve market success. These factors collectively underpin Charles Zhu’s positive outlook and Buy rating for Kura Oncology.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $40.00 price target.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KURA in relation to earlier this year.